Charlotte C. Sun, Dr.P.H., M.P.H.

Peer-Reviewed Articles

1. Suidan RS, Sun CC, Schneider AK, Lu KH, Giordano SH, Meyer LA. Determination of quality of life-related health utilities for surgical complications in ovarian cancer. Gynecol Oncol 185:101-107, 2024. e-Pub 2024. PMID: 38377761.
2. Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer 130(7):1061-1071, 2024. e-Pub 2023. PMID: 38009662.
3. Vranes C, Zhao H, Noer MC, Fu S, Sun CC, Harrison R, Ramirez PT, Høgdall CK, Giordano SH, Meyer LA. Secondary validation of an ovarian cancer-specific comorbidity index in a US population. Int J Gynecol Cancer 33(5):749-754, 2023. e-Pub 2023. PMID: 36863760.
4. Huepenbecker SP, Fu S, Sun CC, Zhao H, Primm KM, Giordano SH, Meyer LA. ASO Visual Abstract: Medicaid Expansion and Postoperative Mortality in Women with Gynecologic Cancer-A Difference-in-Difference Analysis. Ann Surg Oncol 30(3):1520-1521, 2023. PMID: 36289120.
5. Huepenbecker SP, Fu S, Sun CC Zhao H, Primm KM, Giordano SH, Meyer LA. Medicaid Expansion and Postoperative Mortality in Women with Gynecologic Cancer: A Difference-in-Difference Analysis. Ann Surg Oncol 30(3):1508-1519, 2023. e-Pub 2022. PMID: 36310311.
6. Prescott LS, Vergote I, Sun CC, Bodurka DC, Coleman RL. Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort. Int J Gynecol Cancer 33(1):1-9, 2023. e-Pub 2023. PMID: 36356982.
7. Gershenson DM, Cobb LP, Westin SN, Zhang Y, Jazaeri A, Malpica A,Sun CC. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol Oncol 167(2):139-145, 2022. e-Pub 2022. PMID: 36137845.
8. Huepenbecker SP, Fu S, Sun CC, Zhao H, Primm KM, Giordano SH, Meyer LA. Medicaid expansion and 2-year survival in women with gynecologic cancer: a difference-in-difference analysis. Am J Obstet Gynecol 227(3):482.e1-482.e15, 2022. e-Pub 2022. PMID: 35500609.
9. Huepenbecker SP, Sun CC, Fu S, Zhao H, Primm K, Rauh-Hain JA, Fleming ND, Giordano SH, Meyer LA. Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States. Int J Gynecol Cancer 32(9):1153-1163, 2022. e-Pub 2022. PMID: 36166208.
10. Gershenson DM, Sun CC, Westin SN, Eyada M, Cobb LP, Nathan LC, Sood AK, Malpica A, Hillman RT, Wong KK. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol 165(3):560-567, 2022. e-Pub 2022. PMID: 35606067.
11. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res 27(23):6354-6365, 2021. e-Pub 2021. PMID: 34518313.
12. Huepenbecker SP, Sun CC Fu S, Zhao H, Primm K, Giordano SH, Meyer LA. Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States. Cancer 127(22):4151-4160, 2021. e-Pub 2021. PMID: 34347287.
13. Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol 225(1):68.e1-68.e11, 2021. e-Pub 2021. PMID: 33549538.
14. Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol 161(1):56-62, 2021. e-Pub 2021. PMID: 33536126.
15. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol 224(2):191.e1-191.e15, 2021. e-Pub 2020. PMID: 32805208.
16. Gershenson DM, Cobb LP, Sun CC. Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors. Gynecol Oncol 159(3):601-603, 2020. e-Pub 2020. PMID: 33019983.
17. Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, Sood AK, Wong KK, Silva EG, Gershenson DM. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol 158(3):653-658, 2020. e-Pub 2020. PMID: 32709538.
18. Dottino JA, He W, Sun CC, Zhao H, Fu S, Rauh-Hain JA, Suidan RS, Lu KH, Giordano SH, Meyer LA. National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer 30(8):1195-1202, 2020. e-Pub 2020. PMID: 32616627.
19. Bednar EM, Sun CC, McCurdy S, Vernon SW. Assessing relatives' readiness for hereditary cancer cascade genetic testing. Genet Med 22(4):719-726, 2020. e-Pub 2019. PMID: 31857708.
20. Harrison R, Zhao H, Sun CC Fu S, Armbruster SD, Westin SN, Rauh-Hain JA, Lu KH, Giordano SH, Meyer LA. Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer 30(2):187-192, 2020. e-Pub 2019. PMID: 31843871.
21. Harrison RF, He W, Fu S, Zhao H, Sun CC Suidan RS, Woodard TL, Rauh-Hain JA, Westin SN, Giordano SH, Meyer LA. National Patterns of Care and Fertility Outcomes for Reproductive-aged Women with Endometrial Cancer or Atypical Hyperplasia. Am J Obstet Gynecol 221(5):474.e1-474.e11, 2019. e-Pub 2019. PMID: 31128110.
22. Suidan RS, He W, Sun CC, Zhao H, Rauh-Hain JA, Fleming ND, Lu KH, Giordano SH, Meyer LA. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol 221(2):136.e1-136.e9, 2019. e-Pub 2019. PMID: 30965052.
23. Dottino JA, He W, Sun CC, Zhao H, Fu S, Lu KH, Meyer LA. Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes. Gynecol Oncol 154(2):405-410, 2019. e-Pub 2019. PMID: 31208738.
24. Sun CC, Meyer LA, Daniels MS, Bodurka DC, Nebgen DR, Burton-Chase AM, Lu KH, Peterson SK. Women's preferences for cancer risk management strategies in Lynch Syndrome. Gynecol Oncol 152(3):514-521, 2019. PMID: 30876497.
25. Suidan RS, He W, Sun CC, Zhao H, Smith GL, Klopp AH, Fleming ND, Lu KH, Giordano SH, Meyer LA. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol 152(3):439-444, 2019. PMID: 30876486.
26. Meyer LA, Shi Q, Lasala J, Iniesta MD, Lin HK, Nick AM, Williams L, Sun CC, Wang XS, Lu KH, Ramirez PT. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol 152(3):501-508, 2019. PMID: 30876495.
27. Bednar EM, Sun CC, Camacho B, Terrell J, Rieber AG, Ramondetta LM, Freedman RS, Lu KH. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic. Gynecol Oncol 152(2):328-333, 2019. e-Pub 2018. PMID: 30528888.
28. Taylor JS, He W, Harrison R, Zhao H,Sun CC, Lu KH, Giordano SH, Meyer LA. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol 151(2):269-274, 2018. e-Pub 2018. PMID: 30253875.
29. Meyer LA, He W, Sun CC, Zhao H, Wright AA, Suidan RS, Dottino J, Alejandro Rauh-Hain J, Lu KH, Giordano SH. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol 150(3):451-459, 2018. e-Pub 2018. PMID: 29961559.
30. Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, Sun CC, Chisholm GB, Lu KH. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. Gynecol Oncol 150(1):79-84, 2018. e-Pub 2018. PMID: 29735278.
31. Suidan RS, Sun CC, Cantor SB, Mariani A, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. Three lymphadenectomy strategies in low-risk endometrial carcinoma: a cost-effectiveness analysis. Obstet Gynecol 132(1):52-58, 2018. e-Pub 2018. PMID: 29889752.
32. Armbruster SD, Sun CC, Westin SN, Bodurka DC, Ramondetta L, Meyer LA, Soliman PT. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol 149(3):484-490, 2018. e-Pub 2018. PMID: 29622276.
33. Schlumbrecht M, Sun CC, Huang M, Milbourne A, Bodurka D. Gynecologic cancer survivor preferences for long-term surveillance. BNC Cancer Apr 3(18 (1)):375, 2018. PMID: 29614979.
34. Shah JS, Guerra R, Bodurka DC, Sun CC, Chisholm GB, Woodard TL. Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members. Gynecol Oncol 147(3):497-502, 2017. e-Pub 2017. PMID: 28941656.
35. Suidan RS, He W, Sun CC, Zhao H, Ramondetta LM, Badgwell BD, Bodurka DC, Lu KH, Giordano SH, Meyer LA. Treatment patterns, outcomes, and costs for bowel obstruction in ovarian cancer. Int J Gynecol Cancer 27(7):1350-1359, 2017. e-Pub 2017. PMID: 28574929.
36. Soliman PT, Westin SN, Dioun S, Sun CC, Euscher E, Munsell MF, Fleming ND, Levenback C, Frumovitz M, Ramirez PT, Lu KH. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol 146(2):234-239, 2017. e-Pub 2017. PMID: 28528918.
37. Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol 146(2):399-404, 2017. e-Pub 2017. PMID: 28610746.
38. Brown AJ, Thaker PH, Sun CC, Urbauer DL, Bruera E, Bodurka DC, Ramondetta LM. Nothing left to chance? The impact of locus of control on physical and mental quality of life in terminal cancer patients. Support Care Cancer 25(6):1985-1991, 2017. e-Pub 2017. PMID: 28175997.
39. Brown AJ, Shen MJ, Urbauer D, Taylor J, Parker PA, Carmack C, Prescott L, Rosemore C, Kolawole E, Sun CC, Ramondetta L, Bodurka DC. The advance care planning readiness scale: Development and validation of a measure of willingness to discuss and acceptance of end-of-life care in gynecologic cancer patients. Int J Gynecol Cancer 27(4):838-846, 2017. PMID: 28399031.
40. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 35(10):1103-1111, 2017. e-Pub 2017. PMID: 28221866.
41. Suidan RS, He W, Sun CC, Zhao H, Fleming ND, Ramirez PT, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol 145(1):55-60, 2017. e-Pub 2017. PMID: 28131529.
42. Dalton HJ, Fleming ND, Sun CC, Bhosale P, Schmeler KM, Gershenson DM. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. Gynecol Oncol 145(1):37-40, 2017. e-Pub 2017. PMID: 28139261.
43. Taylor JS, Marten CA, Munsell MF, Sun CC, Potts KA, Burzawa JK, Nick AM, Meyer LA, Myers K, Bodurka DC, Aloia TA, Levenback CF, Lairson DR, Schmeler KM. The DISINFECT Initiative: Decreasing the Incidence of Surgical INFECTions in Gynecologic Oncology. Ann Surg Oncol 24(2):362-368, 2017. e-Pub 2016. PMID: 27573526.
44. Iglesias DA, Zhang Q, Celestino J, Sun CC, Yates MS, Schmandt RE, Lu KH. Lean body weight and metformin are insufficient to prevent endometrial hyperplasia in mice harboring inactivating mutations of PTEN. Oncology 92(2):109-114, 2017. e-Pub 2016. PMID: 27931017.
45. Pakish JB, Lu KH, Sun CC, Burzawa JK, Greisinger A, Smith FA, Fellman B, Urbauer DL, Soliman PT. Endometrial cancer associated symptoms: A case-control study. J Womens Health (Larchmt) 25(11):1187-1192, 2016. e-Pub 2016. PMID: 27254529.
46. Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun CC, O'Malley DM, Wright AA. Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer. JAMA 1(2(11)):1427-1433, 2016. PMID: 27442965.
47. Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol, 2016. e-Pub 2016. PMID: 27601552.
48. Ganeshan D, Bhosale P, Wei W, Ramalingam P, Mudasiru-Dawodu E, Gershenson D,Sun CC, Iyer R. Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer. Abdom Radiol (NY) 41(8):1589-1595, 2016. e-Pub 2016. PMID: 26969496.
49. Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Frumovitz MM, Lu KH, Bodurka DC. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv 10(2):261-70, 2016. e-Pub 2015. PMID: 26245979.
50. Taylor JS, Brown AJ, Prescott LS, Sun CC, Ramondetta LM, Bodurka DC. Dying well: How equal is end of life care among gynecologic oncology patients?. Gynecol Oncol 140(2):295-300, 2016. e-Pub 2015. PMID: 26706661.
51. Kim YJ, Munsell MF, Park JC, Meyer LA, Sun CC, Brown AJ, Bodurka DC, Williams JL, Chase DM, Bruera E, Ramondetta LM. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol 139(3):553-8, 2015. e-Pub 2015. PMID: 26432043.
52. Ramondetta LM, Meyer LA, Schmeler KM, Daheri ME, Gallegos J, Scheurer M, Montealegre JR, Milbourne A, Anderson ML, Sun CC. Avoidable tragedies: Disparities in healthcare access among medically underserved women diagnosed with cervical cancer. Gynecol Oncol 139(3):500-5, 2015. e-Pub 2015. PMID: 26498912.
53. Gershenson DM, Sun CC, Wong KK. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br J Cancer 113(9):1254-8, 2015. e-Pub 2015. PMID: 26484411.
54. Arms RG, Sun CC, Burzawa JK, Fleming ND, Nick AM, Rallapalli V, Westin SN, Meyer LA, Ramirez PT, Soliman PT. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol 138(3):727-30, 2015. e-Pub 2015. PMID: 26197762.
55. Brown AJ, Sun CC, Urbauer DL, Bodurka DC, Thaker PH, Ramondetta LM. Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients. Gynecol Oncol 138(2):388-93, 2015. e-Pub 2015. PMID: 25988961.
56. Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, Malpica A, Sun CC. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: Results of a large single-institution registry of a rare tumor. J Clin Oncol 33(24):2675-82, 2015. e-Pub 2015. PMID: 26195696.
57. Brown AJ, Sun CC, Urbauer D, Zhukovsky DS, Levenback C, Frumovitz M, Thaker PH, Bodurka DC, Ramondetta LM. Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer 23(7):2025-32, 2015. e-Pub 2014. PMID: 25519758.
58. Crane EK, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol 136(1):25-9, 2015. e-Pub 2014. PMID: 25448453.
59. Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol 125(3):640-5, 2012. e-Pub 2012. PMID: 22387451.
60. Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, Schmeler K, Deavers M. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 125(3):661-6, 2012. e-Pub 2012. PMID: 22406638.
61. Worley MJ, Anwandter C, Sun CC, dos Reis R, Nick AM, Frumovitz M, Soliman PT, Schmeler KM, Levenback CF, Munsell MF, Ramirez PT. Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecol Oncol 125(1):241-4, 2012. e-Pub 2012. PMID: 22240566.
62. Frumovitz M, Kriseman ML, Sun CC, Blumenthal-Barby J, Sood AK, Bodurka DC, Soliman PT. Unverifiable Accomplishments and Publications on Applications for Gynecologic Oncology Fellowships. Obstet Gynecol 119(3):504-8, 2012. PMID: 22353948.
63. Ramondetta LM, Urbauer D, Brown AJ, Richardson G, Thaker PH, Koenig HG, Levenback C, Sun CC. Work related stress among gynecologic oncologists. Gynecol Oncol 123(2):365-9, 2011. e-Pub 2011. PMID: 21777966.
64. Soliman PT, Frumovitz M, Sun CC, Dos Reis R, Schmeler KM, Nick AM, Westin SN, Brown J, Levenback CF, Ramirez PT. Radical hysterectomy: A comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol 123(2):333-6, 2011. e-Pub 2011. PMID: 21872911.
65. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group Study. Cancer. e-Pub 2011. PMID: 22072418.
66. Schlumbrecht MP, Sun CC, Wong KN, Broaddus RR, Gershenson DM, Bodurka DC. Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer 117(16):3741-9, 2011. e-Pub 2011. PMID: 21319148.
67. Schmeler KM, Sun CC, Malpica A, Deavers MT, Bodurka DC, Gershenson DM. Low-grade serous primary peritoneal carcinoma. Gynecol Oncol 121(3):482-6, 2011. e-Pub 2011. PMID: 21397305.
68. Ramondetta L, Brown A, Richardson G, Urbauer D, Thaker PH, Koenig HG, Gano JB, Sun C. Religious and Spiritual Beliefs of Gynecologic Oncologists May Influence Medical Decision Making. Int J Gynecol Cancer 21(3):573-81, 2011. PMID: 21436706.
69. Lacour RA, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, Brown J, Gano JB, Burke TW, Ramondetta LM. A Phase II Trial of Paclitaxel and Carboplatin in Women with Advanced or Recurrent Uterine Carcinosarcoma. Int J Gynecol Cancer 21(3):517-22, 2011. PMID: 21436700.
70. Schlumbrecht MP, Gallagher CM, Sun CC, Ramondetta LM, Bodurka DC. Ethics Consultation on a Gynecologic Oncology Service: An Opportunity for Physician Education. J Cancer Educ 26(1):183-7, 2011. e-Pub 2010. PMID: 20835927.
71. Vineyard MA, Daniels MS, Urbauer DL, Deavers MT, Sun CC, Boerwinkle E, Bodurka DC, Gershenson DM, Crawford J, Lu KH. Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary. Gynecol Oncol 120(2):229-32, 2011. e-Pub 2010. PMID: 21126756.
72. Agarwal S, Schmeler KM, Ramirez PT, Sun CC, Nick A, Dos Reis R, Brown J, Frumovitz M. Outcomes of patients undergoing radical hysterectomy for cervical cancer of high-risk histologic subtypes. Int J Gynecol Cancer 21(1):123-7, 2011. PMID: 21178574.
73. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. e-Pub 2010. PMID: 21192063.
74. Frumovitz M, Etchepareborda M, Sun CC, Soliman PT, Eifel PJ, Levenback CF, Ramirez PT. Primary malignant melanoma of the vagina. Obstet Gynecol 116(6):1358-65, 2010. PMID: 21099603.
75. Ready KJ, Daniels MS, Sun CC Peterson SK, Northrup H, Lu KH. Obstetrics/Gynecology Residents' Knowledge of Hereditary Breast and Ovarian Cancer and Lynch Syndrome. J Cancer Educ Epub ahead of print(3):401-4, 2010. e-Pub 2010. PMID: 20186516.
76. Brandt AC, Tschirgi ML, Ready KJ, Sun CC, Darilek S, Hecht J, Arun BK, Lu KH. Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer 9(3):479-87, 2010. e-Pub 2010. PMID: 20431955.
77. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B. Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors. J Clin Oncol 28(27):4214-20, 2010. e-Pub 2010. PMID: 20733129.
78. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol 116(2 Pt 1):269-73, 2010. PMID: 20664385.
79. Wong KK, Tsang YTM, Deavers MT, Mok SC, Zu Z, Sun CC, Malpica A, Wolf JK, Lu KH, Gershenson DM,. BRAF Mutation is rare in Advanced Stage Low-Grade Ovarian Serous Carcinomas. The American Journal of Pathology 177(4):1611-7. e-Pub 2010. PMID: 20802181.
80. Kwon JS, Daniels MS, Sun CC, Lu KH. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol Epub ahead of print(4):675-82, 2010. e-Pub 2009. PMID: 19841329.
81. Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz M, Bodurka DC, Sood AK. Pelvic fractures after radiotherapy for cervical cancer: implications for Survivors. Cancer 116(3):625-30, 2010. PMID: 20052724.
82. Tung CS, Sun CC, Schlumbrecht MP, Meyer LA, Bodurka DC. Survival after intestinal perforation: can it be predicted?. Gynecol Oncol 115(3):349-53, 2009. e-Pub 2009. PMID: 19765809.
83. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48-52, 2009. e-Pub 2009. PMID: 19361839.
84. Frumovitz M, Sun CC, Schmeler KM, Deavers MT, Dos Reis R, Levenback CF, Ramirez PT. Parametrial Involvement in Radical Hysterectomy Specimens for Women With Early-Stage Cervical Cancer. Obstet Gynecol 114(1):93-99, 2009. PMID: 19546764.
85. Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer 115(9):1867-74, 2009. PMID: 19241422.
86. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4):836-47, 2009. e-Pub 2009. PMID: 19194760.
87. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 2009. PMID: 19280625.
88. Frumovitz M, Sun CC, Jhingran A, Schmeler KM, Dos Reis R, Milam MR, Soliman PT, Taylor K, Ramirez PT. Radical hysterectomy in obese and morbidly obese women with cervical cancer. Obstet Gynecol 112(4):899-905, 2008. PMID: 18827134.
89. Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, Lu KH. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 113(2):326-35, 2008. PMID: 18506736.
90. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3487-95, 2008. PMID: 18640929.
91. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3496-502, 2008. PMID: 18640930.
92. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833-46; discussion 846-8. e-Pub 2008. PMID: 18471707.
93. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108(3):510-4, 2008. e-Pub 2007. PMID: 18155273.
94. Westin SN, Bustillos D, Gano JB, Fields MM, Coker AL, Sun CC, Ramondetta LM. Social factors affecting treatment of cervical cancer: ethical issues and policy implications. Obstet Gynecol 111(3):747-51, 2008. PMID: 18310380.
95. Jones KL, Saucier JM, Sun CC, Bevers MW, Ramondetta LM, Brown J, Smith JA. Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinics. J Oncol Pharm Pract 14(1):31-6, 2008. PMID: 18337438.
96. Du XL. Sun CC. Milam MR. Bodurka DC. Fang S.. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. International Journal of Gynecological Cancer 18(4):660-669, 2008.
97. Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25(33):5158-64. e-Pub 2007. PMID: 17925543.
98. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246(1):52-60, 2007. PMID: 17592291.
99. Frumovitz M, dos Reis R, Sun CC, Milam MR, Bevers MW, Brown J, Slomovitz BM, Ramirez PT. Comparison of total laparoscopic and abdominal radical hysterectomy for patients with early-stage cervical cancer. Obstet Gynecol 110(1):96-102, 2007. PMID: 17601902.
100. Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 105(3):625-9, 2007. e-Pub 2007. PMID: 17320156.
101. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105(2):404-8, 2007. e-Pub 2007. PMID: 17292461.
102. Tseng JF. Pisters PW. Lee JE. Wang H. Gomez HF. Sun CC. Evans DB.. The learning curve in pancreatic surgery. Surgery 141(5):694-701, 2007.
103. dos Reis R. Frumovitz M. Milam MR. Capp E. Sun CC. Coleman RL. Ramirez PT. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecologic Oncology 107(3):458-463, 2007.
104. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM, Pearson HC, Berenson A, Ramirez PT, Lu KH, Bodurka DC. Are women ready for the HPV vaccine?. Gynecol Oncol 103(1):151-4, 2006. e-Pub 2006. PMID: 16551476.
105. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. The BRK Tyrosine Kinase is Expressed in High-Grade Serous Carcinoma of the Ovary. Cancer Biol Ther 5(9):1136-41, 2006. PMID: 16855388.
106. Wolf JK, Bodurka DC, Verschraegen C, Sun CC, Branham D, Jenkins AD, Atkinson N, Gershenson DM. A Phase II trial of oral capecitabine in patients with platinum - and taxane - refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol 102(3):468-74, 2006. e-Pub 2006. PMID: 16516276.
107. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 108(3 Pt 1):515-20, 2006. PMID: 16946209.
108. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108(2):361-8, 2006. PMID: 16880307.
109. Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun CC, Bodurka DC. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 106(11):2452-8, 2006. PMID: 16639738.
110. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261-9, 2006. PMID: 16421367.
111. Ramondetta LM. Sun CC. Hollier L. Jarrett L. Folloder J. Tortolero-Luna G. Hughes A. Jhingran A. Brown J. Advanced cervical cancer treatment in Harris County: pilot evaluation of factors that prevent optimal therapy. Gynecologic Oncology 103(2):547-553, 2006.
112. Zighelboim I. Ramirez PT. Gao F. Slomovitz BM. Sun CC Frumovitz M. Jhingran A. Levenback C.. Retroperitoneal lymph node resection in patients with cervical cancer. Surgical Oncology 15(2):79-83, 2006.
113. Schmeler KM, Soliman PT, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Endometrial cancer in young, normal-weight women. Gynecol Oncol 99(2):388-92, 2005. e-Pub 2005. PMID: 16051336.
114. Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 23(30):7428-36, 2005. PMID: 16234510.
115. Tangjitgamol S, Ramirez PT, Sun CC, See HT, Jhingran A, Kavanagh JJ, Deavers MT. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. Int J Gynecol Cancer 15(4):646-56, 2005. PMID: 16014119.
116. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219-27, 2005. e-Pub 2004. PMID: 15538640.
117. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 105(3):575-80, 2005. PMID: 15738027.
118. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen L, Allen B, Conrad P, Terdiman J, Sun CC, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecologic Malignancy as a “Sentinel Cancer” for Women with HNPCC. Obstetrics & Gynecology 105(3):569-74, 2005.
119. Ramirez PT, Sun CC, Vidal CI, Schimp V, Slomovitz BM, Bevers MW, Bodurka DC. Outcomes of hysteroscopy and hysterectomy in breast cancer patients. Cancer Therapy:in press, 2005.
120. Ramondetta LM, Jenkins AD, Sun CC, Johnston T, Wolf JK, Bodurka DC, Brown J, Atkinson EN, Levenback C. Phase II Trial of Capecitabine in Recurrent Squamous Cell Carcinoma of the Cervix. Gynecol Oncol 97(3):840-844, 2005. PMID: 15882895.
121. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Gomez HF, Sun CC, Crane CH, Wolff RA, Evans DB. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8(8):935-49; discussion 949-50, 2004. PMID: 15585381.
122. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95(1):133-8, 2004. PMID: 15385122.
123. Tseng JF, Kronowitz SJ, Sun CC, Perry AC, Hunt KK, Babiera GV, Newman LA, Singletary SE, Mirza NQ, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Robb GL, Kuerer HM. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer 101(7):1514-23, 2004. PMID: 15378473.
124. Frumovitz M, Slomovitz BM, Singh DK, Broaddus RR, Abrams J, Sun CC, Bevers M, Bodurka DC. Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J Am Coll Surg 199(3):388-93, 2004. PMID: 15325608.
125. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22(15):3126-32, 2004. PMID: 15284264.
126. Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P, Lu KH. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?. Obstet Gynecol 104(2):255-60, 2004. PMID: 15291996.
127. Smith JA, Kindo CC, Kurian S, Whitaker LM, Burke C, Wachel B, Sun CC, Weaver CL, Danielson MG, Fitzgerald MA, Munsell M, Zandstra FA, Bodurka DC. Evaluation of patient chemotherapy education in a gynecology oncology center. Support Care Cancer 12(8):577-83, 2004. e-Pub 2004. PMID: 15168104.
128. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM, Lu KH. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 94(2):456-62, 2004. PMID: 15297188.
129. Schimp VL, Worley C, Brunello S, Levenback CC, Wolf JK, Sun CC, Bodurka DC, Ramirez PT. Vacuum-assisted closure in the treatment of gynecologic oncology wound failures. Gynecol Oncol 92(2):586-91, 2004. PMID: 14766251.
130. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun CC, Bodurka DC, Gershenson DM. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98(4):758-64, 2003. PMID: 12910520.
131. Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF, Kavanagh JJ, Gershenson DM. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?. Gynecol Oncol 87(1):118-28, 2002. PMID: 12468352.
132. Robinson JB, Sun CC, Bodurka-Bevers D, Im DD, Rosenshein NB. Cavitational ultrasonic surgical aspiration for the treatment of vaginal intraepithelial neoplasia. Gynecol Oncol 78(2):235-41, 2000. PMID: 10926809.
133. Bodurka-Bevers D, Sun CC, Gershenson DM. Pharmacoeconomic considerations in treating ovarian cancer. Pharmacoeconomics 17(2):133-50, 2000. PMID: 10947337.
134. Cantor SB, Sun CC, Tortolero-Luna G, Richards-Kortum R, Follen M. A comparison of C/B ratios from studies using receiver operating characteristic curve analysis. J Clin Epidemiol 52(9):885-92, 1999. PMID: 10529029.
135. Cantor SB, Mitchell MF, Tortolero-Luna G, Bratka CS, Bodurka DC, Richards-Kortum R. Cost-effectiveness analysis of diagnosis and management of cervical squamous intraepithelial lesions. Obstet Gynecol 91(2):270-7, 1998. PMID: 9469288.

Invited Articles

1. Meyer L, Suidan R,Sun CC, Westin S, Coleman RL, Mills GB. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Rev Qual Life Cancer Care 1(3):231-238, 2016. e-Pub 2016. PMID: 30906877.
2. Bodurka DC, Huang M, Sun CC. Caring for Cancer Patients in the Future: A Perfect Storm on the Horizon?. Oncology (Williston Park) 24(14):1351-2, 2010. PMID: 21294483.
3. Sun CC, Ramirez PT, Bodurka DC. Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 4(1):18-29, 2007. PMID: 17183353.
4. Bodurka DC, Sun CC, Gerhsenson DM. Review on, "Reproductive issues in the gynecologic cancer patient" Carter J, et al. Oncology 21(5):598-609, 2007.
5. Bodurka DC, Sun CC. Sexual function after gynecologic cancer. Obstet Gynecol Clin North Am 33(4):621-630, 2006. PMID: 17116505.
6. Sun CC, Frumovitz M, Bodurka DC. Quality of life and gynecologic malignancies. Curr Oncol Rep 7(6):459-65, 2005. PMID: 16221383.
7. Bodurka-Bevers D,Sun CC, Gershenson DM. Economic issues related to ovarian cancer. Oncology Economics 1(9):40-47, 2000.

Manuals, Teaching Aids, Other Teaching Publications

1. Sun CC. Ovarian Cancer: Quality of Life Issues, National Ovarian Cancer Coalition, 2005.
2. Sun CC. Helping Cancer Patients with Quality of Life Treatment Decisions. American College of Obstetricians and Gynecologists ACOG UPDATE, 2005.

Other Articles

1. Sun CC The University of Texas M.D. Anderson Cancer Center, Preference Assessment Inventory (P.A.I.), U.S., copyright, 2003.

Editorials

1. Bodurka DC, Sun CC, Frumovitz MMF. Quality of life in cervix cancer survivors – What matters the most in the long-term?. Gynecologic Oncology 97:307-309, 2005.

Abstracts

1. Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol 117(2):236-244, 2018. e-Pub 2017. PMID: 28787528.
2. Zhang Y, Coletta AM, Allen PK, Parikh AM, Cox-Mattin M, Meyer LA, Sun CC, Basen-Engquist KM, Lu KH, Klopp AH. Perirenal adiposity is associated with lower progression-free survival from ovarian cancer. Int J Gynecol Cancer 28(2):285-292, 2018. PMID: 29303933.
3. Shah JS, Bodurka DC, Sun CC, Chisholm G, Woodard TL. Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of SGO members. Gynecologic Oncology 145(Suppl 1):175-176, 2017.
4. Suidan RS, He W, Sun CC||, Zhao H, Smith GL, Klopp AH, Fleming ND, Lu KH, Giordano SH, Meyer LA. . National trends, outcomes and costs of radiation therapy in the management of low-and high-intermediate risk endometrial cancer. Gynecologic Oncology 145(Suppl 1):133-134, 2017.
5. Meyer LA, Nick AM, Shi Q, Iniesta MD, Lasala JD, Harris M, Sun CC, Lu KH, Ramirez PT. Comparison of longitudinal patient reported outcomes on an enhanced recovery pathway in patients with ovarian cancer undergoing primary vs interval cytoreductive surgery. Gynecologic Oncology 145(Suppl 1):207-208, 2017.
6. Meyer L, Shi Q, Iniesta M, Harris M, Sun CC, Lasala J. Comparison of patient reported symptom burden in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. J Clinical Oncology 35(No 15 (Suppl May)):5557-5557, 2017.
7. Suidan RS, He W, Sun CC, Zhao H, Lu KH, Giordano SH. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. J Clinical Oncology 35(No 15 (Suppl May)):6602-6602, 2017.
8. Bednar EM, Oakley HD, Sun CC, Daniels MS, Rayes N, Yates M, Nick AM, Mills GB, Gonzalez-Rosa K, Lu KH. Achieving universal BRCA1 and BRCA2 genetic testing with a novel care delivery model. Accepted for poster presentation at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer 141(Suppl 1):80, 2016.
9. Meyer LA, He W, Sun CC||, Zhao H, Suidan RS, Lu KH, Giordiano SH. Uptake and outcomes associated with neoadjuvant chemotherapy in the elderly: a population based analysis. Accepted for a poster presentation at the Society for Gynecologic Oncology 47th Annual Meeting on Women's Cancer, 2016.
10. Soliman PT, Nick AM, Sun CC, Dioun SM, Pal N, Frumovitz M, Ramirez SV, Lu KH, Westin SN. Obesity significantly reduces the sentinel lymph node detection rate in women with endometrial cancer. Accepted for featured poster presentation at the Society for Gynecologic Oncology 47th Annual Meeting on Women's Cancer 141(Suppl 1):31, 2016.
11. Bednar EM, Oakley HD, Sun CC, Westin SN, Lu KH. Universal Germline BRCA Testing of Ovarian Cancer Patients and Implications for Treatment. Accepted for a Poster presentation at the American Society of Clinical Oncology Annual Meeting, J Clin Oncol 34(Suppl), 2016.
12. Nebgen DR, Holman LL, Hurteau J, Keeler E, Chisholm GB,Sun CC, Lu KH. Prophylactic salpingectomy with delayed oophorectomy (PSDO): Feasibility study in women with BRCA mutations. J Clin Oncol 34(Suppl), 2016.
13. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A,Sun CC. Hormonal maintenance therapy for women with low grade serous carcinoma of the ovary or peritoneum. J Clin Oncol 34(Suppl), 2016.
14. Meyer L, Suidan R, He W, Sun CC, Zhao H, Westin S, Soliman P, Woodard T, Lu K, Giordano S. Endometrial hyperplasia and cancer in young women: A study of national patterns of care over time and pregnancy outcomes. 16th Biennial Meeting of the International Gynecologic Cancer Society, 2016.
15. Suidan RS, He W, Sun CC, Soliman PT, Ramirez PT, Zhao H, Fleming ND, Westin SN, Lu KH, Giordano SH, Meyer LA. Impact of body mass index on surgical costs and morbidity for women with endometrial carcinoma/hyperplasia. J Clin Oncol 34, 2016.
16. Suidan RS, He W,Sun CC, Zhao H, Ramondetta LM, Badgwell BD, Bodurka DC, Lu KH, Giordano SH, Meyer LA. Treatment patterns and outcomes for bowel obstruction in elderly ovarian cancer patients: A population-based analysis. Gynecologic Oncology 141(Suppl 1):131, 2016.
17. Meyer LA, He W, Sun CC, Zhao H, Suidan RS, Lu KH, Giordano SH, Bodurka DC. Uptake and outcomes associated with neoadjuvant chemotherapy in the elderly: A population-based analysis. Gynecologic Oncology 141(Suppl 1):169, 2016.
18. Armbruster SD,Sun CC, Soliman PT, Westin SN, Bodurka DC, Ramondetta LM, Bradford AM, Basen-Engquist K. Prospective assessment of patient perception and quality of life in gynecologic patients after pelvic exenteration. J Clin Oncol 34(Suppl), 2016.
19. Pentz RD, Farmer ZL, Green MJ, Daugherty C, Hlubocky FJ, Peterson SK, Sun CC, Lewis CM, Owonikoko TK, Khuri FR and Harvey RD. Assessing patients’ values when standard-of-care options are exhausted. Journal of Clinical Oncology ASCO Annual Meeting Proceedings 29(15_supplement):9108, 2011.
20. Huang M, Djordjevic B, Urbauer D, Westin SN, Sun CC, Burzawa JK, Meyer L, Bodurka DC, Broaddus R and Lu KH.. Molecular analysis of endometrial pathogenesis in Lynch syndrome. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings 29(15_supplemental):9108, 2011.
21. Iglesias D,Sun CC, Langstraat C, Bakkum-Gamez J, El-Nashar S, Keeler E, Gershenson D, Lu L. Management and clinical outcomes of women with BRCA1/2 mutations found to have occult cancers at the time of risk-reducing salpingo-oophorectomy. Gynecologic Oncology 120(Supplement 1):S59-S60, 2011.
22. Bodurka DC, Jhingran A, Ramondetta LM, Eifel PJ, Crane CH, Phan AT, Urbauer D, Frumovitz MM, Elting LS, Sun CC. Visual analog scale (VAS) and time trade-off (TTO) preferences for side effects (SE) of chemoradiation (chemoXRT): A comparison of patients (pts) and caregivers (CG). J Clin Oncol 28(15s), 2011.
23. Schlumbrecht MP, Sun CC, Westin SN, Zandstra F, Denton K, Rhodes H, Gonzales DA, Garcia EA, Levenback CL, Bodurka DC. Lifestyle modification in cervical cancer survivors: an ongoing need. Gyncologic Oncology 120(Supplement 1):S109, 2011.
24. Huang M, Westin SN, Sun CC, Meyer L, Tung C, Urbauer D, Bodurka DC. Menopausal Symptoms and Hormone Replacement Use: The Gynecologic Cancer Survivors’ Perspective. Gynecologic Oncology 120(Supplement 1):S59-S60, 2011.
25. Ramondetta LM, Jhingran A, Frumovitz M, Delgado M, Brown J, Eifel P, Palencia J,Sun CC. Protective effects of spirituality and religiosity in underserved women with cervical cancer (CXCA). Support Care Cancer 19(Suppl 2):S67-S370, 2011.
26. Schlumbrecht MP, Sun CC, Wong KN, Broaddus RR, Gershenson DM, Bodurka DC. The Role of Smoking in Low-Grade Serous Ovarian Carcinoma. Gynecologic Oncology 116(Issue 3):S123-S124, 2010.
27. Schlumbrecht MP, Gallagher CM, Sun CC, Ramondetta LM, Bodurka DC.. Ethics Consultation on a Gynecologic Oncology Service: A Learning Opportunity for Physicians. Gynecologic Oncology 116(Issue 3):S57-S58, 2010.
28. Westin SN, Sun CC, Schlumbrecht MP, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Soliman PT, Lu KH, Bodurka DC. Persistent obesity among endometrial cancer survivors: A teachable moment?. Gynecologic Oncology 116(Issue 3):S81-S82, 2010.
29. Ramondetta LM, Fields MM, Brown J, Rodriquez S, Folloder J, Sun CC. Barriers to Cervical Cancer Screening in Medically Underserved Women: Still More To Be Done. Gynecologic Oncology 113(Issue 3):S39-S40, 2010.
30. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC Sood AK, Brown J, Gershenson DM, Ramirez PT. Prevalence of lymph node involvement in primary mucinous carcinoma of the ovary. Gynecologic Oncology 116(Issue 3):S112-S113, 2010.
31. Daniels MS, Vineyard M, Urbauer D, Deavers M, Sun CC, Boerwinkle E, Bodurka D, Gershenson D, Lu K.. Is low grade serous ovarian cancer part of the hereditary breast and ovarian cancer tumor spectrum?. Gynecologic Oncology 116(Issue 3):S98-S99, 2010.
32. Sun CC, Peterson SK, White KG, Boyd-Rogers S, Schmeler KM, Bodurka DC, Lu KH. Patient preferences for risk management strategies for women with Lynch syndrome. Familial Cancer 9(4):732-733, 2010.
33. Gershenson DM, Sun CC, Malpica A, Deavers M, Bodurka DC, Schmeler KM. Low-grade serous primary peritoneal carcinoma. J Clin Oncol 28(15s), 2010.
34. Bodurka D, Sun CC, Jhingran A, Urbauer D, Levenback C, Eifel P, Ramondetta L, Ramirez P, Frumovitz M, Schover L. A Longitudinal Evaluation of Sexual Functioning and Quality of Life in Cervical Cancer Survivors. Gyncologic Oncology 120(Supplement 1):S81-S82, 2010.
35. Kwon JS, Daniels MS, Sun CC, Lu KH. Opportunities for future cancer prevention by BRCA mutation testing of women with ovarian cancer. Gynecologic Oncology 112(S98), 2009.
36. Sun CC, Ramondetta LM, Jhingran A, Eifel PJ, Crane C, Phan AT, Frumovitz MM, Elting LS, Bodurka DC. Patient preferences for chemoradiation related side effects. Journal of Clinical Oncology 27(suppl):e20604, 2009.
37. Tung CS, Sun CC, Cohen L, Frenkel M, Ramondetta LM, Smith JA, Parker P, Bodurka DC. Complementary and alternative medicine: What do oncology healthcare providers think?. Journal of Clinical Oncology 27(suppl):e20614, 2009.
38. Ostler DA, Malpica A, Sun CC, Perna AG, Diwan AH, Lazar AJ, Deavers MT, Prieto VG. Comparative study of methods to determine depth of invasion in vulvar squamous cell carcinoma. Laboratory Investigation 88(Supplement 1s):216A-217A, 2008.
39. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Kavanagh JJ. Recurrent low-grade serous carcinoma of the ovary is relatively chemoresistant. Gynecologic Oncology 108(3 Supplement 1):S5, 2008.
40. Bodurka DC, Deavers M, Tian C, Sun CC, Ozols RF, Gershenson DM. Ancillary study of GOG 158: Survival based on reclassification to a two-tier grading system for serous carcinoma of the ovary. Gynecologic Oncology 108(3 Supplement):S33, 2008.
41. Lacour RA, White KG, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik T, Urbauer DL, Sun CC, Bodurka DC, Gershenson DM, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecologic Oncology 108(3 Supplement):S59, 2008.
42. Meyer LA, Westin SN, Lacour RA, Urbauer DL, Sun CC, Daniels MS, Schmeler KM, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA 1/2: Missed Opportunities. Gynecologic Oncology 108(3 Supplement):S67-68, 2008.
43. Lacour RA, Daniels MS, Westin SN, Meyer LA, Choubey V, Blank SV, MacDonald HR, Roman L, Estes JM, Barnes M, Teoh D, Powell B, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Do BRCA mutations confer a survival advantage in all cases of advanced-stage ovarian cancer?. Gynecologic Oncology 108(3 Supplement):S108-109, 2008.
44. Sun CC, Peterson S, Lu KH, White K, Daniels M, Boyd-Rogers S, Westin SN, Bodurka DC. Women’s preferences for cancer screening strategies and prophylactic surgery. Gynecologic Oncology 108(3 Supplement):S137, 2008.
45. Sun CC, Westin SN, Lacour RA, Meyer LA, Tung CS, Urbauer DL, Frumovitz M, Gershenson DM, Lu KH, Bodurka DC. Health concerns of long-term survivors of gynecologic cancers. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):727S, 2008.
46. Westin SN, Sun CC, Lacour RA, Meyer LA, Tung CS, Urbauer DL, Frumovitz M, Lu KH, Gershenson DM, Bodurka DC. Survivors of gynecologic malignancies (GYN CA): Impact of treatment on health and well-being. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):299S, 2008.
47. Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz MM, Bodurka DC, Sood AK. Pelvic fractures following radiation therapy for cervical cancer: implications for survivors. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):300S, 2008.
48. Meyer L, Westin SN, Lacour RA, Urbauer DL, Schmeler KM, Daniels MS, Sun CC Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA 1/2: missed opportunities. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):300S, 2008.
49. Sun CC, Aguilliard J, Jhingran A, Eifel P, Crane CH, Phan A, Ramondetta LM, Frumovitz MF, Elting L, Bodurka DC. Preferences for Side Effects of Chemoradiation: Focus on Nausea and Vomiting. Supportive Care in Cancer 16(6):734, 2008.
50. Westin SN, Sun CC, Lacour RA, Urbauer DL, Lu KH, Bodurka DC. Survivors of Gynecologic Malignancies (Gyn Ca): Impact of Treatment on Health and Well-being. Supportive Care in Cancer 16(6):752, 2008.
51. Thaker P, Sun CC, Palmer L, Pei BL, Bruera E, Ramondetta L. Spirituality, Coping and Control In a Palliative Care Setting. Supportive Care in Cancer 16(6):719, 2008.
52. Ramondetta L, Johnson A, Sun CC, Achanta L, Kavanagh J. A Survey On the Role of Religion and Spirituality in Gynecologic Oncologists. Supportive Care in Cancer 16(6):718, 2008.
53. Milam MR, Sun CC, Landen CN, Schmeler KM, Lu KH, Coleman RL, Ramirez PT. Neoadjuvant Chemotherapy Improves Perioperative Outcomes in Patients with Advanced Epithelial Ovarian Cancer. Gynecologic Oncology 104(3S1):S43, 2007.
54. Frumovitz MF, dos Reis R, Sun CC, Milam M, Brown J, Bevers M, Ramirez PT. A Comparison of Total Laparoscopic vs. Abdominal Radical Hysterectomy for Cervical Cancer. Gynecologic Oncology 104(3S1):S25, 2007.
55. Westin SN, Sun CC, Lu KH, Milam MR, Schmeler KM, White KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Management Strategies for Women at High Risk for Breast and Ovarian Cancer: Are Women Satisfied?. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):1524, 2007. e-Pub 2007.
56. Sun CC, Westin SN, Lu KH, Milam MR, Schmeler KM, White KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Impact of BRCA 1/2 Testing: Body Image, Sexual Functioning, and Quality of Life (QOL). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):1525, 2007.
57. Lacour RA, Westin SN, Daniels MS, Milam MR, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Survival in advanced-stage ovarian cancer patients with non-Ashkenazi Jewish BRCA mutations. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):5514, 2007.
58. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):5571, 2007.
59. Burke TW, Navo MA, Smith JA, Jung MS, Broaddus R, Iyer RB, Lu KH, Sun CC, Atkinson EN, Ramondetta LM. Phase II trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):5595, 2007.
60. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk-reduction surgeries in patients tested for a BRCA mutation. Accepted for poster presentation at the 2007 Breast Cancer Symposium, 2007.
61. Katz, MHG, Wolff RA, Pisters PWT, Sun CC, Evans DB, Varadhachary GR, Fleming JB, Hwang RF. Borderline Resectable Pancreatic Cancer: The Importance of this Emerging Stage of Disease. Accepted for presentation at the 2007 Southern Surgical Association Annual Meeting, 2007.
62. Frumovitz M,Sun CC, Brown J, dos Reis, R, Milam, M, Levenback CL, Ramirez PT. Total laparoscopic radical hysterectomy in an academic vs community setting. Journal of Minimally Invasive Gynecology 14:48, 2007.
63. Schmeler K, Tortolero-Luna G, Soliman PT, Sun CC, Milam M, Slomovitz B, Gershenson D, Lu K, Williams M, Betts P. Racial/ethnic differences in survival among Texas women with ovarian cancer: A population-based study. Gynecologic Oncology 101:S63-64, 2006.
64. Soliman PT, Tortolero-Luna G, Schmeler K, Milam M, Slomovitz B, Sun CC, Brown J, Gershenson D, Lu K, Williams M, Betts P. Racial/ethnic differences in survival among Texas women with endometrial cancer: A population-based study. Gynecologic Oncology 101:S80, 2006.
65. Schmeler K, Broaddus R, Sun CC, Soliman PT, Milam M, Thornton A, Wu W, Slomovitz B, Gershenson D, Lu K, McCampbell A, Shipley G. Obesity-related endometrial cancers are not molecularly distinct from endometrial cancers arising in normal-weight women. Gynecologic Oncology 101:S101-102, 2006.
66. Schmeler K, Sun CC, Bodurka DC, White K, Soliman PT, Uyei AR, Erlichman J, Arun B, Peterson S, Milam M, Slomovitz B, Gershenson DM, Lu K. Are women with BRCA1/2 mutations choosing prophylactic bilateral salpingo-oophorectomy over surveillance?. Gynecologic Oncology 101:S107, 2006.
67. Thaker P, Sun CC, Bodurka DC, Palmer JL, Pei BL, Willey J, Bruera E, Ramondetta LM. Spirituality and locus of control in a palliative care setting. Gynecologic Oncology 101:S107-108, 2006.
68. Soliman PT, Morris V, Sun CC, Ramirez P, Weaver C, Jennings J, Schmeler K, Slomovitz B, Bodurka DC. No increase in risk associated with primary surgical cytoreduction in women diagnosed with ovarian cancer at an advanced age. Gynecologic Oncology 101:S143-144, 2006.
69. Milam M, Slomovitz B, Schmeler K, Soliman PT, Ramirez P, Sun CC, Eifel P, Ramondetta L, Lu K. Management and patterns of recurrence of women with occult stage II endometrioid endometrial cancer. Gynecologic Oncology 101:S77, 2006.
70. Sun CC, Peterson SK, White KG, Watts BG, Daniels MS, Boyd-Rogers SG, Schmeler KM, Bodurka DC, Lu KH. Preferences for cancer prevention strategies in women with hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology 24(18S):1018, 2006.
71. Thaker PH, Sun CC, Bodurka DC, Palmer J, Pei B, Willey J, Bruera E, Ramondetta L. Spirituality, quality of life, and locus of control in a palliative care setting. Journal of Clinical Oncology 24(18S):690S, 2006.
72. Bodurka DC, Sun CC, Weaver CB, Bethancourt DL, Fitzgerald MA, Wolf JK, Gershenson DM, Kavanagh JJ, Munsell MF, Donato ML. Longitudinal assessment of quality of life of patients with ovarian cancer receiving high-dose or conventional-dose chemotherapy. Journal of Clinical Oncology 23(16S):470s, 2005.
73. Lu KH, Schorge J, Rodabaugh K, Sun CC, Daniels M, White K, Soliman P, Luthra R, Broaddus R. Defining criteria for Lynch/HNPCC in women under 50 with endometrial cancer: Final results of a prospective, multi-center study. Journal of Clinical Oncology 23(16S):848s, 2005.
74. Schmeler K, Soliman P,Sun CC, Oh J, Gershenson D, Slomovitz B, Lu K. Defining endometrial cancer risk factors for young, non-obese women. Gynecologic Oncology 96:1015, 2005.
75. Schmeler KM, Soliman PT, Munsell MF, Daniels MS, White KG, Boyd-Rogers SG, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery for the reduction of gynecologic cancer risk in women with Lynch syndrome/HNPCC. Journal of Clinical Oncology 23(16S):844s, 2005.
76. Slomovitz BM, Burke TW, Soliman PT, Ramondetta LM, Eifel PJ, Jhingran A, Wolf J, Sun CC, Gershenson DM. Patterns of recurrence of uterine papillary serous carcinoma. Gynecologic Oncology 96:947, 2005.
77. Slomovitz BM, Coleman RL, Soliman PT, Ramondetta LM, Wolf J, Sun CC, Gershenson DM. Is there a survival difference between clear cell and serous carcinoma of the endometrium? A stage and age-matched cohort study. Journal of Clinical Oncology 23(16S):474s, 2005.
78. Slomovitz BM, Ramondetta LM, Crotzer C, Soliman P, Schmeler K, Broaddus RR, Sun CC, Gershenson DM, Burke TW, Lu KL ,. Clinical and pathologic review of clear cell carcinoma of the endometrium: a single institution study of 81 patients. poster presentation. 36th Annual Meeting of the Society of Gynecologic Oncologists:accepted for March 2005, 2005.
79. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Pearson HC, Berenson A, Bodurka DC. Are women ready for the cervical cancer vaccine? . Gynecologic Oncology 96:912, 2005.
80. Sun CC, Bodurka DC, Weaver CB, Bethancourt DL, Fitzgerald MA, Wolf JK, Gershenson DM, Kavanagh JJ, Munsell MF, Donato ML. Preferences over time of chemo-experienced versus chemo-naïve patients for treatment-related side effects. Journal of Clinical Oncology 23(16S):784s, 2005.
81. Zighelboim I, Ramirez PT, Sun CC, Frumovitz MM, Jhingran A, Levenback C. Factors That Preclude Resection of Bulky Nodal Metastases in Patients with Cervical Cancer. Gynecologic Oncology 96:989-990, 2005.
82. Frumovitz M, Slomovitz BM, Broaddus RR, Abrams J, Sun CC, Bevers M, Bodurka DC. Endometrial cancer: To stage or not to stage, part II. Gynecologic Oncology 92:487, 2004.
83. Frumovitz M, Sun CC, Schover LR, Jhingran A, Eifel PJ, Bevers TB, Levenback C, Bodurka DC. Quality of Life in Cervix Cancer Survivors: Five Years Posttreatment. Gynecologic Oncology 92:474, 2004.
84. Jenkins AD, Ramondetta L, Johnston T,Sun CC, Wolf JK, Bodurka DC, Atkinson EN, Levenback CF. A Phase II Study of Capecitabine in Recurrent Squamous Cell Carcinoma of the Cervix. Gynecologic Oncology 92:427, 2004.
85. Jhingran A, Bodurka DC, Sun CC, Eifel PJ. Acute toxicity of chemoradiation for cervical cancer. American Radium Society, Napa Valley, CA, 2004.
86. Schimp VL, Sun CC, Jennings J, Soliman P, Bodurka DC. Bowel Obstruction in Ovarian Cancer Patients: Surgical versus Medical Therapy. Gynecologic Oncology 92:453, 2004.
87. Schmeler K, Soliman P, Sun C, Oh J, Slomovitz B, Lu K. Risk factors for endometrial cancer in young, premenopausal, non-obese women. poster presentation. Third Annual American Association for Cancer Research International Conference: Frontiers in Cancer Prevention Research, 2004.
88. See HT, Walker PW, Palmer JL, Basen-Engquist K, Elsayem A, DeGarcia L, Sun CC, Bodurka DC, Kavanagh JJ. Palliative Care Index for Ovarian Cancer. International Gynecologic Cancer Society:544, 2004.
89. Shvartsman HS, Bodurka D, Sun CC, Crispens M, Lu K, Silva E, Gershenson D. Comparative study of disease process and survival in patients with recurrent serous low malignant potential tumor of ovary versus patients with low grade serous carcinoma of the ovary. Meeting Proceedings of the American Society for Clinical Oncology, 39th Annual Meeting 22:452, 2004.
90. Slomovitz BM, Broaddus RR, Sneige N, Tarco E, Soliman PT, Wu W, Sun CC, Schmandt R, Burke TW, Gershenson DM, Lu KH. Her-2/neuexpression and amplification in uterine papillary serous carcinoma (UPSC). Gynecologic Oncology 92:435-436, 2004.
91. Slomovitz BM, Ramirez PT, Bodurka DC, Sun CC, Oh JC, Diaz P, Broaddus RR, Soliman PT, Gershenson DM, Lu KH. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? . Gynecologic Oncology 92:404-405, 2004.
92. Slomovitz BM, Wu W, Soliman PT, Broaddus RR, Sun CC, Bodurka DC, Gershenson DM, Lu KH. Clinical and molecular characteristics of patients who develop breast cancer and uterine papillary serous carcinoma (UPSC). Gynecologic Oncology 92:423-424, 2004.
93. Soliman PT, Slomovitz BM, Broaddus R, Sun CC, Oh J, Gershenson DM, Lu KH. Synchronous Primary Cancers of the Endometrium and Ovary: A single institution review of 75 cases. Gynecologic Oncology 92:482-483, 2004.
94. Soliman PT, Slomovitz BM, Sun CC, Gershenson DM, Lu KH. Endometrial cancer screening should be considered in women with colon cancer and one family member with an HNPCC-associated Cancer. Gynecologic Oncology 92:434, 2004.
95. Sun CC, Weaver CB, Fitzgerald MA, Wolf JK, Ramirez PT, Gershenson DM, Bodurka DC. Preferences (PREF) of physicians (MDs) and patients (pts) with ovarian cancer (OVCA): Who values what? . Gynecologic Oncology 92:501, 2004.
96. Tangjitgamol S, Ramirez PT, Sun CC, See HT, Jhingran A, Kavanagh JJ, Deavers MT. Expression of HER-2/NEU, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progresterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. International Gynecologic Cancer Society:222, 2004.
97. Tseng JF, Kronowitz, SJ, Hunt KK, Sun CC, Babiera GV, Singletary E, Mirza NQ, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Robb GL, Kuerer HM. The Rate of Immediate Reconstruction Following Mastectomy for Breast Cancer Varies by Patient Race. Annals of Surgical Oncology 11(Suppl 2):S32, 2004.
98. Tseng JF, Sun CC, Abdalla EK, Vauthey J, Pisters PW, Lee JE, Evans DB. Resection of the Superior Mesenteric-Portal Vein for Pancreatic Adenocarcinoma: Margin Status and Survival Duration. Gastroenterology 126(4, Suppl.2):A-769, 2004.
99. Weaver C, Sun CC, Schover LR, Aday L, Bodurka DC. Assessment of quality of life and sexual activity after treatment for cervix cancer. AcademyHealth 20th Annual Research Meeting, CD-ROM Conference Proceedings:43, 2003.
100. Bodurka DC, Frumovitz M, Sun CC, Ramirez PT, Bevers MW, Gershenson DM. Laparoscopy For Probable Ovarian Cancer: Less May Not Be More. Gynecologic Oncology 88(2):244, 2003.
101. Bodurka DC, Sun CC, Weaver CB, Jennings J, Melancon CH, Bevers MW, Wolf JW, Ramirez PT, Gershenson DM, Lairson DR. Ovarian cancer (OV CA): The cost of caregiving. Meeting Proceedings of the American Society for Clinical Oncology, 39th Annual Meeting 22:527, 2003.
102. Frumovitz M, Ramirez PT, Tortolero-Luna G, Bodurka DC, Sun CC, Malpica A, Levenback C. Groin recurrence in patients who underwent lymphatic mapping for vulvar malignancy. Int J Gyn Cancer 13(Supp 1):17, 2003.
103. Lu K, Beahm E, Arun B, Bodurka-Bevers D,Sun CC, Miller M, Hunt K, Ames F, Strong L, Meric-Bernstam, F. Coordinated Prophylactic Surgical Management for Women with Breast-Ovarian Cancer Syndrome. Proceedings of the 2nd Annual International Conference on Frontiers in Cancer Prevention Research:100 (# C190), 2003.
104. Ramirez PT, Vidal C, Schimp VL, Sun CC, Slomovitz BM, Bevers MW, Bodurka DC. Indications and Outcomes of Hysteroscopy and Hysterectomy in Breast Cancer Patients. Gynecologic Oncology 88(2):216, 2003.
105. Schimp VL, Sun CC, Wolf JK, Bodurka DC, Levenback CL, Ramirez PT. Vacuum-Assisted Closure in the Treatment of Gynecologic Oncology Wound Failures. Gynecologic Oncology 88(2):203-204, 2003.
106. Sun CC, Bodurka DC, Lu KH, Efron B, Andersen A, Bevers TBB, Gershenson DM, Bast RC. Perceptions of OVCA Risk and Screening: Differences between women with a history of breast cancer (WHxBr) and women with no history of breast cancer (WnoBr). Gynecologic Oncology 88(2):239-240, 2003.
107. Sun CC, Bodurka DC, Weaver CB, Fitzgerald MA, Wolf JK, Levenback C, Kavanagh JJ, Palmer L, Gershenson DM, Rubenstein EB. Preferences (PREF) for Side Effects (SEs) of Chemotherapy (CHEMO): How Long is Too Long and How Much is Too Much? . Meeting Proceedings of the American Society for Clinical Oncology, 39th Annual Meeting 22:743, 2003.
108. Sun CC, Bodurka DC, Weaver C, Andersen R, Gershenson DM, Bast RC. Knowledge of ovarian cancer screening in a low-risk population. AcademyHealth 20th Annual Research Meeting, CD-ROM Conference Proceedings:39, 2003.
109. Sun CCS, Slomovitz BM, Frumovitz M, Weaver CB, Lu KH, Gershenson, DM, Bodurka DC. Preference (utility) assessment in patients with gynecologic malignancies: The M. D. Anderson Experience. European Journal of Cancer Supplements 1(3):S16, 2003.
110. Sun CC Borden CL, Young VN, Charneco L, Rojas M, Lerten F, Goldstein S, Morris M, Gershenson DM, Bodurka DC. A feasibility study of assessing patient preferences and quality of life in culturally-diverse women with cervix cancer. Academy for Health Services Research and Health Policy Annual Meeting, CD-ROM Conference Proceedings. Part 1 1:48, 2002.
111. Anderson ML, Bodurka DC, White K, Sun CC, Wolf JK, Burke TW. Outcome of patients undergoing surgical resection of recurrent leiomyosarcoma. Gynecologic Oncology 84(3):528, 2002.
112. Sun CC, Borden CL, Donato ML, Cooke S, Basen-Engquist K, Fitzgerald MA, Kavanagh JJ, Gershenson DM, Bodurka DC. Patient preferences for side-effects of chemotherapy for ovarian cancer: do preferences change over time? . Gynecologic Oncology 84(3):493, 2002.
113. Sun CC, Borden CL, Charneco L, Young VN, Rojas M, Lerten F, Goldstein S, Morris M, Gershenson DM, Bodurka DC. Chemoradiation for cervix cancer: cultural differences in preferences for side-effects. Programs/Proceedings of the American Society for Clinical Oncology, 38th Annual Meeting. Publication number 2599 21(2), 2002.
114. Sun CC, Bodurka DC, Donato ML, Borden C, Rubenstein EB. Nausea and vomiting side-effects of cancer therapies: preference assessments from patients, health care providers and healthy women. Supportive Care in Cancer 10(4):378, 2002.
115. Sun CC Bodurka DC, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF, Kavanagh JJ, Gershenson DM. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?. 3rd Annual Kelsey Research Foundation's Health Services and Outcomes Research Conference, 2002.
116. Wolf JK, Sun CC, Verschraegen CF, Jenkins AD, Branham DW, Bodurka DC. A phase II study of Xeloda in patients with chemotherapy resistant recurrent ovarian cancers. Programs/Proceedings of the American Society for Clinical Oncology, 38th Annual Meeting. Publication number 893 21(1), 2002.
117. Sun CC, Bodurka-Bevers, D, Borden CL, Rojas MS, Lerten F, Goldstein S, Gershenson DM, Morris M. A Pilot Study to Assess Patient Preferences for Side Effects of Chemoradiation. Gynecologic Oncology 80(2):288, 2001.
118. Sun CC, Bodurka-Bevers, Gershenson DM, Lairson DL. Estimating Quality-Adjusted Survival For Women at High-Risk for Developing Breast Cancer: A Monte Carlo Markov Model Incorporating 3 Different Sets of Preferences. Academy for Health Services Research and Health Policy Annual Meeting CD-ROM Conference Proceedings:Abstract #67, 2001.
119. Sun CC, Donato ML, Cooke S, Borden CL, Basen-Engquist K, Fitzgerald MA, Kavanagh JJ, Gershenson DM, Bodurka-Bevers D ;. Ovarian Cancer (OVCA) Patients (PTS) Undergoing High-Dose Chemotherapy (HDCT) With Peripheral Blood Stem Cell Support (PBSCS): Preferences For Toxicities Over Time. Programs/Proceedings of the American Society for Clinical Oncology, 37th Annual Meeting:Publication # 2576, 2001.
120. Bodurka-Bevers, DC, Sun CC, Cantor SB, Rieger P, Martin CG, Mills GB, Gershenson DM. Preferences Over Time of Women at High-Risk of Breast/Ovarian Cancer Who Undergo Genetic Counseling/Ovarian Cancer Screening. Program/Proceedings of the American Society of Clinical Oncology 19:444a, 2000.
121. Sun CC Bodurka-Bevers DC, Rieger P, Martin CG, Mills GB, Gershenson DM, Cantor SB. Patient Preferences for Outcomes in Women at High-Risk for Breast/Ovarian Cancer – Who and How You Ask Matters. Program/Proceedings of the American Society of Clinical Oncology 19:435a, 2000.
122. Sun CC, Bodurka-Bevers D, Cantor SB, Gershenson DM, Lairson D. Preferences Using Standard Gamble and Time Trade-off: Societal versus Patient Perspectives. Association for Health Services Research Annual Meeting CD-ROM Conference Proceedings:Abstract #93, 2000.
123. Sun CC, Bodurka-Bevers D, Borden CL, Cantor SB, Rieger PT, Mills GB, Gershenson DM, Lairson DR. Do Preferences Vary By Method of Preference Assessment or Patient Group?. Medical Decision Making 20(4):482, 2000.
124. Bratka C, Rubenstein E, Martin C, Chau Q, Elting L. Predicting Emergency Center (EC) Outcomes For Cancer Patients (pts). Program/Proceedings of the American Society of Clinical Oncology 16:422a, 1997.
125. Bratka CS, Elting L, Martin C, Chau Q, Rubenstein EB. Patients’ Ratings of Illness and Stability, Correlation with Clinicians’ Ratings and Emergency Center Outcomes. Supportive Care in Cancer 5(2):173, 1997.
126. Cantor SB, Rubenstein EB, Elting LS, Frisbee-Hume S, Bratka CS, Stedman D, Rolston KVI. Economic Evaluation of Management Strategies for Low-Risk Febrile Neutropenic Cancer Patients. Program/Proceedings of the American Society of Clinical Oncology 16:419a, 1997.
127. Cantor SB, Bratka CS, Richards-Kortum R, Mitchell MF. A ‘league table’ for receiver operating characteristic curve analysis? . Medical Decision Making 16:466, 1996.

Book Chapters

1. Bodurka DC, Sun CC, Basen-Engquist KM. Quality of Life in the Gynecologic Cancer Patient. In: Gynecologic Cancer: Controversies in Management. Elsevier Ltd, 785-794, 2004.
2. Bodurka DC Sun CC. Quality of Life and Sexual Functioning. In: Gynecologic Cancer, in press, 2000.
3. Rubenstein EB, Elting LS, Sun CC, Rolston KVI. Outpatient Management of Neutropenic Fever: Antibiotics, Growth Factors or Both? . In: Clinical Applications of Cytokines and Growth Factors. Kluwer Academic Publishers, 1998.
4. Rubenstein EB Sun CC. Outpatient Management of Chemotherapy-Treated Patients. In: Supportive Care in Cancer: A Handbook for Oncologists. Marcel Dekker, Inc, 1998.